Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1321. Genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC)

for hereditary nonpolyposis colorectal cancer (HNPCC) Bloomington MN: Institute for Clinical Systems Improvement (ICSI) 2002 Authors' objectives This review aims to assess the available evidence on the effectiveness of genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC). Authors' conclusions With regard to genetic testing for hereditary nonpolyposis colon cancer (HNPCC) the ICSI Technology Assessment Committee finds: Genetic testing of HNPCC can reduce the number of surveillance (...) Genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC) Genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC) Genetic testing for hereditary nonpolyposis colorectal cancer (HNPCC) Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement. Genetic testing

2002 Health Technology Assessment (HTA) Database.

1322. Screening for colorectal cancer in adults

Screening for colorectal cancer in adults Screening for colorectal cancer in adults Screening for colorectal cancer in adults Pignone M P, Rich M, Teutsch S, Berg A, Lohr K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pignone M P, Rich M, Teutsch S, Berg A, Lohr K. Screening for colorectal cancer in adults. Rockville: Agency (...) for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 7. 2002 Authors' objectives This review aims to assess the effectiveness and cost-effectiveness of different colorectal cancer screening tests. Authors' conclusions Colorectal cancer screening is effective in reducing mortality from colorectal cancer. Current data are insufficient to determine the most effective or cost-effective strategy for screening, although all major strategies have favorable cost

2002 Health Technology Assessment (HTA) Database.

1323. [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptability]

techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptability] Vitoria-Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-02-02. 2002 Authors' objectives

Make a systematic review of scientific literature in order to determine the sensitivity and specificity of the techniques used in the diagnosis of the malign neoplastic lesion and benign neoplasia of the colon.
Determine the use of the endoscopic and radiological techniques (...) [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptability] Tecnicas endoscopicas y radiologicas en el diagnostico de cancer colo-rectal. Evaluacion de la variabilidad de uso y aceptabilidad [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptability] Tecnicas endoscopicas y radiologicas en el diagnostico de cancer colo-rectal

2002 Health Technology Assessment (HTA) Database.

1324. Imatinib for gastrointestinal stromal tumours

Imatinib for gastrointestinal stromal tumours Imatinib for gastrointestinal stromal tumours Imatinib for gastrointestinal stromal tumours Totman M Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Totman M. Imatinib for gastrointestinal stromal tumours. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton (...) 2002: 9 Authors' objectives This study aims to assess the clinical effects of imatinib alone or in combination with other treatments in people with gastrointestinal stromal tumour (GIST), compared with other systemic, surgical or supportive treatments. Authors' conclusions We found no evidence of effects of imatinib in people with resectable or benign GIST, many of whom have an excellent prognosis following resection. In people with unresectable or metastatic GIST, prognosis is reported as poor. We

2002 Health Technology Assessment (HTA) Database.

1325. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer

Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 33. 2002 Authors' objectives To provide guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Authors' conclusions Guidance 1.1 On the balance

2002 Health Technology Assessment (HTA) Database.

1326. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. (Abstract)

Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon. The safety and efficacy of LAC for colon cancer are unknown, and the nature and magnitude of any quality-of-life (QOL) benefit resulting from LAC for colon cancer is also unknown.To compare short-term QOL outcomes after LAC vs open (...) assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy (mean [median], 3.2 [3] vs 4.0 [4] days; P<.001) and oral analgesics (mean [median], 1.9 [1] vs 2.2 [2] days; P =.03).Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy. Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer, this procedure should

2002 JAMA Controlled trial quality: predicted high

1327. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. (Abstract)

Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. This randomised controlled trial is examining the hypothesis that a single flexible sigmoidoscopy screening offered at around age 60 years can lower the incidence and mortality of colorectal cancer. We report here on acceptability, safety, feasibility, and yield.Men and women aged 55-64 years, in 14 UK centres, who responded to a mailed questionnaire that they would (...) attend for flexible sigmoidoscopy screening if invited, were randomly assigned screening or control (ratio one to two). The control group was not contacted. Small polyps were removed during screening, and colonoscopy was undertaken if high-risk polyps (three or more adenomas, size 1 cm or greater, villous, severely dysplastic, or malignant) were found.Of 354,262 people asked about their interest in having flexible sigmoidoscopy screening, 194,726 (55%) responded positively, and 170,432 eligible

2002 Lancet Controlled trial quality: uncertain

1328. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. (Abstract)

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. This randomised trial compared three chemotherapy regimens in the first-line treatment of advanced colorectal cancer, in terms of their effect on overall and progression-free survival; other endpoints included toxicity, symptom palliation, and quality of life.905 patients were randomly assigned the de Gramont regimen (n=303; folinic acid 200 (...) (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed. An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity. Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.The deGramont and Lokich regimens were similar

2002 Lancet Controlled trial quality: uncertain

1329. Laparoscopic-assisted resection of colorectal malignancies

) and the Cochrane Library (Issue 2, 1999) were searched. The search terms included combinations of 'colectomy', 'resection', 'hemicolectom*', 'laparoscop*' , 'neoplasm', 'endoscp*', 'colorectal' and 'cancer'. A full list of terms was provided in the report. Following the initial search, which considered studies reported in any language, the search was restricted to English language papers if articles in other languages were not considered to be superior. Given the large volume of studies identified (...) colorectal resection. While the authors stated that studies of interventions with abdominoperineal resection, transverse colectomy or total colectomy were excluded, it was also stated that three papers did include these invalid procedures (papers shown in Table 2 of the report). Participants included in the review Studies of people with adenocarcinoma of the colon were eligible. In vivo or in vitro studies of tumour cell spread in animals were also eligible. The authors did not provide details about

2002 DARE.

1330. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer

Participants with colorectal cancer were eligible for inclusion in the review if they were initially diagnosed with metastatic disease, or had developed metastatic disease after having received adjuvant 5FU-based (first-line) therapy, or had proved resistant to previous 5FU treatment for metastatic disease. Further details of the participants' characteristics were provided in the review. Outcomes assessed in the review The outcomes assessed in the qualifying studies had to include at least one (...) they present. Implications of the review for practice and research Practice: The authors state that in the sub-section 'Factors relevant to the NHS', currently about 30% of patients who die of colorectal cancer receive chemotherapy for advanced disease, while another 15% have the capacity to benefit from such chemotherapy. The majority of those who receive chemotherapy presumably receive a 5FU-based regimen, and probably most of these are the de Gramont infusional regimen. If chemotherapy is extended

2002 DARE.

1331. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis

2002; 122(1): 78-84 PubMedID Other publications of related interest Greenberg ER, Baron JA, Freeman DH Jr, et al. Reduced risk of large bowel adenomas among aspirin users. Journal of the National Cancer Institute 1993;85:912-6. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. New England Journal of Medicine 1993;329:1977-81. Muller A D, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy: a case control study of 32,702 veterans (...) . In general, the external validity of the study was low. Implications of the study The study results supported the use of COL to prevent CRC in patients in the general population. In patients already taking aspirin to prevent cardiovascular disease, COL improved the overall cost-effectiveness of the preventive strategy. Source of funding None stated. Bibliographic details Suleiman S, Rex D K, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology

2002 NHS Economic Evaluation Database.

1332. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness

Betz Foundation. Bibliographic details Reyes C M, Allen B A, Terdiman J P, Wilson L S. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 2002; 95(9): 1848-1856 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Adaptor Proteins, Signal Transducing; Base Pair Mismatch; Carrier Proteins; Colorectal Neoplasms, Hereditary Nonpolyposis /diagnosis /economics /genetics; Cost (...) Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness Reyes C M, Allen B A, Terdiman J P

2002 NHS Economic Evaluation Database.

1333. Cost-effectiveness of a single colonoscopy in screening for colorectal cancer

Cost-effectiveness of a single colonoscopy in screening for colorectal cancer Cost-effectiveness of a single colonoscopy in screening for colorectal cancer Cost-effectiveness of a single colonoscopy in screening for colorectal cancer Sonnenberg A, Delco F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of single or repeated colonoscopy for the screening of colorectal cancer (CRC). Single colonoscopy was performed at 65 years of age, while repeated colonoscopy was performed every 10 years starting at the age of 50. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population was the general population in the USA. Setting The setting was the community. The economic study

2002 NHS Economic Evaluation Database.

1334. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer

Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 NHS Economic Evaluation Database.

1335. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer Full Text available with Trip Pro

for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7. Netten A, Dennett J. Unit costs of health and social care. Kent: University of Kent, Personal Social Services Research Unit; 1998. Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents, Phytogenic /administration & Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Camptothecin /administration & Colorectal Neoplasms /drug therapy; Costs and Cost Analysis; England (...) Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer Cunningham D, Falk S, Jackson D Record

2002 NHS Economic Evaluation Database.

1336. Screening for colorectal cancer: the cost to find an advanced adenoma

into consideration when referring to the results obtained by this study. Source of funding None stated. Bibliographic details McGrath J S, Ponich T P, Gregor J C. Screening for colorectal cancer: the cost to find an advanced adenoma. American Journal of Gastroenterology 2002; 97(11): 2902-2907 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Adenoma /economics /prevention & Barium Sulfate; Canada; Colonoscopy /economics; Colorectal Neoplasms /economics /prevention & Contrast Media; Cost-Benefit (...) Screening for colorectal cancer: the cost to find an advanced adenoma Screening for colorectal cancer: the cost to find an advanced adenoma Screening for colorectal cancer: the cost to find an advanced adenoma McGrath J S, Ponich T P, Gregor J C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2002 NHS Economic Evaluation Database.

1337. Screening for colorectal cancer

et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Eng J Med 1993;328:1365-71. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7. Manus B, Brägelmann R, Armbrecht U et al. Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre. European Journal of Cancer Prevention 1996;5:49-55 (...) on April 11, 2000. The latest version of this report is not available in English. Cancer of the colon and rectum is third most common cause of death from cancer. Each year, approximately 2 500 people in Sweden die because of the disease. The risk of being affected is the same in men and women and increases with age. One way to reduce morbidity and mortality is to detect cancer at an early stage where surgical intervention has good results. General screening in the population can be conducted

2002 Swedish Council on Technology Assessement

1338. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. (Abstract)

Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Aspirin may decrease colorectal cancer incidence, but its role as an adjunct to or substitute for screening has not been evaluated.To examine the potential cost-effectiveness of aspirin chemoprophylaxis in relation to screening.Markov model.Literature on colorectal cancer epidemiology, screening, costs, and aspirin chemoprevention (1980-1999).General U.S. population.50 to 80 years (...) of age.Third-party payer.Aspirin therapy in patients screened with sigmoidoscopy every 5 years and fecal occult blood testing every year (FS/FOBT) or colonoscopy every 10 years (COLO).Discounted cost per life-year gained.When a 30% reduction in colorectal cancer risk was assumed, aspirin increased costs and decreased life-years because of related complications as an adjunct to FS/FOBT and cost $149 161 per life-year gained as an adjunct to COLO. In patients already taking aspirin, screening with FS/FOBT

2001 Annals of Internal Medicine

1339. Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. (Abstract)

Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Microsatellite instability is a hallmark of mismatch repair deficiency in hereditary nonpolyposis colorectal cancer and results from mutations in the mismatch repair genes MLH1 or MSH2 or from gene inactivation associated with DNA methylation. The Bethesda guidelines were established to identify patients with colorectal cancer who should be tested for microsatellite (...) instability.To assess the Bethesda guidelines for detection of microsatellite instability and to determine the role of MLH1 promoter methylation in colorectal cancer.Prospective cohort study.Tertiary care referral center in Frankfurt, Germany.125 consecutive patients with colorectal cancer.Patients were assessed according to the Bethesda guidelines, and tumor specimens were analyzed for microsatellite instability. Patients with microsatellite instability were tested for MLH1 promoter methylation and MLH1

2001 Annals of Internal Medicine

1340. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. (Abstract)

analysis.National colorectal cancer registry data, the Creighton International Hereditary Colorectal Cancer Registry, Medicare claims records, and published literature.Patients with newly diagnosed colorectal cancer and their siblings and children.Lifetime (varies depending on age at screening).Societal.Initial office-based screening to determine eligibility (based on personal and family cancer history), followed by tumor testing for microsatellite instability. Those with microsatellite instability were offered (...) Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. The National Cancer Institute has published consensus guidelines for universal screening for hereditary nonpolyposis colorectal cancer (HNPCC) in patients with newly diagnosed colorectal cancer.To determine the cost-effectiveness of screening compared with standard care in eligible patients with colorectal cancer and their siblings and children.Cost-effectiveness

2001 Annals of Internal Medicine